期刊文献+

胆总管结石患者胆汁中菌群特点及药物敏感性分析 被引量:1

Distribution of bile pathogenic bacteria and antibiotic drug sensitivity analysis in patients with common bile duct stones
暂未订购
导出
摘要 目的了解胆总管结石患者胆汁病原菌分布特点及其耐药情况。方法对72例胆总管结石患者的胆汁标本行病原菌培养及药物敏感性试验。结果 72例胆汁标本共培养菌株60株,其中革兰阴性菌45株(75%),革兰阳性菌12株(20%),真菌3株(5%);排列前3位的细菌依次为大肠埃希菌(30%)、屎肠球菌(12%)、肺炎克雷伯杆菌肺炎亚种(10%)。革兰阴性菌对亚胺培南、阿米卡星敏感率最高(均为95%),对氨苄青霉素的耐药率高达89%;革兰阳性菌对万古霉素、替考拉宁、利奈唑烷敏感率最高(均为100%),对青霉素G耐药率82%。结论胆总管结石患者胆汁细菌以革兰阴性杆菌为主,治疗一般首先考虑应用革兰阴性菌敏感率高的抗生素。 Objective To analysis the distribution of bile pathogenic bacteria and the change of drug sensitivity in patients with CBDS, and to guide rational antibiotics application. Methods Bile specimens of 72 patients with CBDS were collected through endoscopic retrograde pancreatic angiography (ERCP) treat- ment. Pathogenic bacteria cultivation and drug sensitivity test were applied. Results Sixty strains were trained, including gram-negative bacterium 45 strains (75%) , gram-positive 12 strains(20% ) , fungi 3 strains(5% ). The top three predominant pathogenic bacteria were escherichia coli ( 30% ), entercoccus faecium ( 12% ), klebsiella pneumoniae (10%). Drug sensitivity showed highest sensitive rate (95%) of gram-negative strains to imipenem, amikacin. The resistant rate of gram-negative strains to ampicillin was up to 89%. The sensitive rate of gram-positive strains to vancomycin, teicoplanin linezolid was the highest (100%). The resistant rate of gram-positive strains to penicillin G was 82%. Conclusions Gram-negative strains remained the commo- nest pathogens in patients with common bile duct stones in this hospital, the application of high rate of gram- negative bacteria sensitive antibiotics should be considered firstly in treatment of such patients.
出处 《新医学》 2013年第10期697-700,共4页 Journal of New Medicine
关键词 胆总管结石 胆汁 细菌 药物敏感性 Choledocholithiasis Bile Bacteria Drug sensitivity
  • 相关文献

参考文献5

二级参考文献28

  • 1姚俊,许亚平,孟鑫,薛翠华,周春锁,付白清.114例胆道感染患者胆汁细菌培养分析[J].临床内科杂志,2006,23(10):677-678. 被引量:27
  • 2Wang G, Hindler JF, Ward KW, et al. Increased vancomycin MIC8 for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period[J]. J Clin Microhiol, 2006,44(11) : 3883-3886.
  • 3The Sanofi-Aventis Group. Teicoplanin (Teicoplanin) [EB/OL]. Accessed July 4,2008. at http:// WWW. sanofi-aventis. co. uk/ products/Tagocid SPC. pdf.
  • 4Brogden RN,Peters DH. Teicoplanin,a reappraisal of its antimicrobial activity, pharmacokinetic properties and therapeutic efficieney[J]. Drugs,2006,47(5) :823-854.
  • 5Tureo TF,Melko GP,Williams JR. Vancomycin intermediateresistant Staphylococcus aureus [J]. Ann Pharmaeother, 2008,32(7-8) : 758.
  • 6Lye D,Athan E, O'Brien D. Teicoplanin hypersensitivity syndrome[J]. Int J Antimierob Agents,2007,29(4) :476-478.
  • 7Wilson AP. Comparative safety of teicoplanin and vaneomycin [J]. Int J Antimicrob Agents,2006,10(2):143-152.
  • 8Voeten M,Landstra AM,Maseland MH,et al. Serious side effects oifrequently used antibiotics in childhood : biliary sludge or stones in-duced by ceftriaxone and thrombocytopenia induced by co - trimox-azole [ J ]. Ned Tijdschr Geneeskd, 2007,151 (23) : 1299 - 1303.
  • 9Hamada T,Yokota K, Ayada K,et al. Detection of Helicobacter he-paticus in human bile samples of patients with biliary disease [ J ].Helicobacter,2009,14(6) :545 -551.
  • 10Zhou D,Zhang Y,Gong W,et al. Are Helicobacter pylori and otherHelicobacter species infection associated with human biliary lithias-is. A meta-analysis[ J]. PLoS One,2011 ,6(11) ;e27390.

共引文献29

同被引文献21

引证文献1

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部